

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10541683	
	Filing Date		2006-04-07	
	First Named Inventor	Frieder SCHWENK		
	Art Unit	1632		
	Examiner Name	Michael C. Wilson		
	Attorney Docket Number	100725-49 (40) KGB		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10541683
Filing Date	2006-04-07
First Named Inventor	Frieder SCHWENK
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	100725-49 (40) KGB

1	FUKUSHIGE, et al; "Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells" Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 7905-7909, September 1992, Genetics	<input type="checkbox"/>
2	LI, et al, "RXRa ablation in skin keratinocytes results in alopecia and epidermal alterations"; Development 128, 675-688 (2001) 675-688, Printed in Great Britain © The Company of Biologists Limited 2001	<input type="checkbox"/>
3	McBURNEY, et al, "Murine PGK-1 Promoter Drives Widespread But Not Uniform Expression in Transgenic Mice"; DEVELOPMENTAL DYNAMICS (1994), 278-293, WILEY-LISS, INC.	<input type="checkbox"/>
4	Okabe et al; "'Green mice' as a source of ubiquitous green cells"; FEBS Letters 407 (1997) 313^31	<input type="checkbox"/>
5	ORBAN et al; "Tissue- and site-specific DNA recombination in transgenic mice"; Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 6861-6865, August 1992, Genetics	<input type="checkbox"/>
6	Ovchinnikov et al; "Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice"; Genesis. 2000 Feb;26(2):145-6.	<input type="checkbox"/>
7	Postic et al; "DNA Excision in Liver by an Albumin-Cre Transgene Occurs Progressively With Age"; genesis 26:149–150 (2000), 2000 Wiley-Liss, Inc.	<input type="checkbox"/>
8	Ray MK, et al; "Development of a transgenic mouse model using rat insulin promoter to drive the expression of CRE recombinase in a tissuespecific manner."; Int J Pancreatol. 1999 Jun;25(3):157-63.	<input type="checkbox"/>
9	Rickert et al; "B lymphocyte-specific, Cre-mediated mutagenesis in mice", Nucleic Acids Research, 1997, Vol. 25, No. 6 1317–1318, 1997 Oxford University Press	<input type="checkbox"/>
10	Saam, et al; "Inducible Gene Knockouts in the Small Intestinal and Colonic Epithelium", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 274, No. 53, Issue of December 31, pp. 38071–38082, 1999,	<input type="checkbox"/>
11	Schlake et al; "Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci.", Biochemistry. 1994 Nov 1;33(43):12746-51.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10541683
Filing Date	2006-04-07
First Named Inventor	Frieder SCHWENK
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	100725-49 (40) KGB

12	Torres et al; "Labotatory Protocols for Conditional Gene Targeting", Oxford University Press 1997	<input type="checkbox"/>
13	Tsien, et al; "Subregion- and Cell Type–Restricted Gene Knockout in Mouse Brain"; Cell, Vol. 87, 1317–1326, December 27, 1996, Copyright ©1996 by Cell Press	<input type="checkbox"/>
14	Urlinger, et al; "Exploring the sequence space for tetracyclinedependent transcriptional activators: Novel mutations yield expanded range and sensitivity"; PNAS July 5, 2000 vol. 97 no. 14 7963–7968	<input type="checkbox"/>
15	Utomo, et al; "Temporal, spatial, and cell type–specific control of Cre-mediated DNA recombination in transgenic mice" 1999 Nature America Inc. • http://biotech.nature.com , NATURE BIOTECHNOLOGY VOL 17 NOVEMBER 1999	<input type="checkbox"/>
16	Yao, et al; "A Novel Tetracycline-Inducible Viral Replication Switch"	<input type="checkbox"/>
17	Agah, et al; Gene Recombination in Postmitotic Cells, "Targeted Expression of Cre Recombinase Provokes Cardiac-restricted, Site-specific Rearrangement in Adult Ventricular Muscle In Vivo"; J. Clin. Invest. © The American Society for Clinical Investigation, Inc., Volume 100, Number 1, July 1997, 169–179	<input type="checkbox"/>
18	Barlow, et al; Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of loxP-flanked gene segments"; Nucleic Acids Research, 1997, Vol. 25, No. 12 2543–2545	<input type="checkbox"/>
19	Brünnin, et al; "A Muscle-Specific Insulin Receptor Knockout Exhibits Features of the Metabolic Syndrome of NIDDM without Altering Glucose Tolerance"; Molecular Cell, Vol. 2, 559–569, November, 1998, Copyright 1998 by Cell Press	<input type="checkbox"/>
20	Chung, et al; "Analysis of Different Promoter Systems for Efficient Transgene Expression in Mouse Embryonic Stem Cell Lines"; Stem Cells. 2002 ; 20(2): 139–145.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Michael Wilson/	Date Considered	08/30/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10541683
Filing Date	2006-04-07
First Named Inventor	Frieder SCHWENK
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	100725-49 (40) KGB

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.